APG Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.49M | Buy |
60,578
+2,636
| +5% | +$282K | 0.02% | 416 |
|
|
2025
Q1 | $5.93M | Sell |
57,942
-2,247
| -4% | -$230K | 0.02% | 428 |
|
|
2024
Q4 | $7.93M | Buy |
+60,189
| New | +$7.93M | 0.02% | 402 |
|
|
2024
Q3 | – | Sell |
-257,315
| Closed | -$33.1M | – | 568 |
|
|
2024
Q2 | $33.1M | Sell |
257,315
-119,803
| -32% | -$15.4M | 0.06% | 270 |
|
|
2024
Q1 | $48.2M | Sell |
377,118
-5,426
| -1% | -$693K | 0.08% | 217 |
|
|
2023
Q4 | $45.6M | Buy |
382,544
+46,685
| +14% | +$5.57M | 0.09% | 217 |
|
|
2023
Q3 | $37.8M | Buy |
335,859
+21,378
| +7% | +$2.41M | 0.08% | 241 |
|
|
2023
Q2 | $27.2M | Sell |
314,481
-12,265
| -4% | -$1.06M | 0.05% | 292 |
|
|
2023
Q1 | $30.4M | Buy |
326,746
+15,466
| +5% | +$1.44M | 0.06% | 285 |
|
|
2022
Q4 | $37.2M | Buy |
311,280
+76,960
| +33% | +$9.19M | 0.07% | 289 |
|
|
2022
Q3 | $25.4M | Sell |
234,320
-89,056
| -28% | -$9.66M | 0.07% | 278 |
|
|
2022
Q2 | $30.2M | Buy |
323,376
+1,466
| +0.5% | +$137K | 0.07% | 278 |
|
|
2022
Q1 | $27.1M | Sell |
321,910
-600
| -0.2% | -$50.6K | 0.05% | 317 |
|
|
2021
Q4 | $24.2M | Buy |
322,510
+314,900
| +4,138% | +$23.6M | 0.04% | 348 |
|
|
2021
Q3 | $630K | Sell |
7,610
-1,500
| -16% | -$124K | ﹤0.01% | 846 |
|
|
2021
Q2 | $748K | Sell |
9,110
-109,346
| -92% | -$8.98M | ﹤0.01% | 830 |
|
|
2021
Q1 | $9.8M | Sell |
118,456
-47,837
| -29% | -$3.96M | 0.02% | 487 |
|
|
2020
Q4 | $13M | Sell |
166,293
-20,695
| -11% | -$1.62M | 0.02% | 514 |
|
|
2020
Q3 | $15.3M | Buy |
186,988
+45,409
| +32% | +$3.72M | 0.03% | 493 |
|
|
2020
Q2 | $15.4M | Buy |
141,579
+40,000
| +39% | +$4.34M | 0.03% | 460 |
|
|
2020
Q1 | $8.79M | Buy |
101,579
+46,579
| +85% | +$4.03M | 0.02% | 577 |
|
|
2019
Q4 | $5.27M | Buy |
+55,000
| New | +$5.27M | 0.01% | 689 |
|